FLT1 and diffuse large B-cell lymphoma: Immunodeficient mice engrafted with human DLBCL treated with antibodies against human or murine VEGFR-1 or VEGFR-2 showed a significant 50% reduction in tumor mass after treatment with human anti-VEGFR-1.